Company Profile

SPR Therapeutics LLC
Profile last edited on: 8/16/2023      CAGE: 66R73      UEI: LWF1M6NK1Z43

Business Identifier: Ultrasound-guided percutaneous peripheral nerve stimulation device
Year Founded
2009
First Award
2005
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

22901 Millcreek Boulevard Suite 110
Cleveland, OH 44122
   (216) 378-9108
   info@sprtherapeutics.com
   www.sprtherapeutics.com/
Location: Single
Congr. District: 11
County: Cuyahoga

Public Profile

With direct ties to Case Western - and itself spinning out of another Case Western start-up (NDI) - SPR Therapeutics, LLC develops and commercializes interventional pain management therapies and medical devices. With their capabilities designated the SPRINTĀ® PNS System, the firm offers a breakthrough treatment designed to "recondition' the central nervous system for significant and sustained relief from chronic pain. Describing themselves as a medical device company developing peripheral nerve stimulation products for pain management clinicians, the firm is organized around the concept of neurostimulation targeting peripheral nerves with the effort being to provide an alternative to spinal cord stimulators for the treatment of chronic pain. The company's primary product is Smartpatch, a percutaneous peripheral nerve stimulation (PNS) system for post-surgical pain following surgeries. The device has applications for operations in knee replacement, thoracotomy, rotator cuff repair; neuropathic pain, nerve surgery, phantom limb pain, and musculoskeletal pains. The firm's products also include Smartpatch short-term therapy for sustained relief; Micropulse long term therapy through implantable PNS system; and Smartpatch MicroLead, which includes a coiled wire construction that fosters rapid tissue ingrowth.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $4,927,725
Project Title: Electrical Stimulation to Reduce Pain and Improve Function After Knee Replacement
2019 2 NIH $4,721,556
Project Title: Peripheral Nerve Stimulation for Amputee Pain
2018 2 DHA $980,969
Project Title: Development of a Specialized Miniature Stimulator System for Non-Opioid Pain Relief
2015 2 NIH $4,208,560
Project Title: Miniature stimulator for temporary therapies

Key People / Management

  Maria E Bennett -- President, CEO and Founder

  Benjamin Austin -- Chief Financial Officer

  Joseph Wilder Boggs -- Chief Scientific Officer

  Mark McDonald -- Senior Director, Manufacturing Operations and Supply Chain

  Steve Pearson -- Director, Strategic Growth

  Devin Sell -- Director of Engineering & Manufacturing

  Kathryn Stager -- Director of Regulatory Affairs and Quality System

  Bob Strother -- Chief Engineer

  Mark Stultz -- Senior Vice President, Market Development

  Geoffrey B Thorpe -- Founder

  David Youngberg -- Vice President, Sales